Nawata H, Takayanagi R, Ohnaka K, Sakai Y, Imasaki K, Yanase T, Ikuyama S, Tanaka S, Ohe K
Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Steroids. 1995 Jan;60(1):28-34. doi: 10.1016/0039-128x(94)00022-5.
The present study was designed to clarify the transcriptional regulation of the human type 1 angiotensin II receptor (AT1) gene and its pathophysiological roles in steroidogenesis by adrenal tumors. A cDNA encoding type 1 angiotensin II receptor (AT1) was isolated from a human liver cDNA library encoding a protein of 359 amino acids with seven transmembrane segments. It is very likely that human has only one type of AT1 receptor, in contrast with rodents. A genomic clone containing 217 bp of exon 1 and 2558 bp of the 5'-flanking region of human AT1 receptor gene was isolated. Its proximal promoter region contained putative TATA and GC boxes, CRE and AP1 sites. Aldosterone-producing adenoma (APA) contained significantly higher levels of mRNA for AT1 and ACTH receptors than normal tissues adjacent to APA. There were no mutations within the cytoplasmic third loops of AT1 and ACTH receptors in APAs examined. APA showed increased expression of the mRNA for P450c11 and decreased expression of the mRNA for P450c17. These results suggest that renin-independent overproduction and clinically observed ACTH-dependent production of aldosterone in APAs may results from the enhanced transcription of P450c11 and ACTH receptor genes. The mechanism of the discordantly increased expression of AT1 receptor in APA remains to be clarified.
本研究旨在阐明人类1型血管紧张素II受体(AT1)基因的转录调控及其在肾上腺肿瘤类固醇生成中的病理生理作用。从人肝脏cDNA文库中分离出编码1型血管紧张素II受体(AT1)的cDNA,其编码一种含有359个氨基酸和七个跨膜区段的蛋白质。与啮齿动物不同,人类很可能只有一种类型的AT1受体。分离出一个基因组克隆,其包含人AT1受体基因外显子1的217 bp和5'侧翼区域的2558 bp。其近端启动子区域包含推定的TATA和GC框、CRE和AP1位点。醛固酮分泌性腺瘤(APA)中AT1和促肾上腺皮质激素(ACTH)受体的mRNA水平明显高于APA旁的正常组织。在所检测的APA中,AT1和ACTH受体的胞质第三环内没有突变。APA显示细胞色素P450c11的mRNA表达增加,细胞色素P450c17的mRNA表达减少。这些结果表明,APA中醛固酮的肾素非依赖性过量产生以及临床上观察到的ACTH依赖性产生可能是由于细胞色素P450c11和ACTH受体基因转录增强所致。APA中AT1受体表达不一致增加的机制仍有待阐明。